Previous 10 | Next 10 |
[[ABBV]], [[AON]], [[AXL]], [[BAH]], [[BR]], [[CBOE]], [[CHTR]], [[CL]], [[CVX]], [[FBP]], [[FLIR]], [[FTS]], [[GT]], [[HON]], [[IPGP]], [[ITT]], [[KKR]], [[LEA]], [[LGND]], [[LHX]], [[LYB]], [[MMP]], [[MO]], [[NVT]], [[NWL]], [[PBI]], [[PEG]], [[PNM]], [[PNW]], [[POR]], [[PQG]], [[PSX]], [[P...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury ® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated...
NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO. The firm is advancing treatments for narcolepsy and ADHD. NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO. For further details see...
Updates 2020 Guidance Introduces Preliminary Financial Outlook for 2021 to 2023 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today’s virtual Investor Day event its senior management reviewed recent business progress and prov...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report third quarter 2020 financial results on October 30, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host th...
HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million. Singapore's ASLAN Pharmaceuticals announced plans to develop ASLAN003, its next-gen dihydroorotate dehydrogenase inhibitor in autoimmune conditions, such as multiple sclerosis. ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe earnings season heats up next week, with high-fliers Netflix (NASDAQ:NFLX), Tesla (NASDAQ:TSLA) and Chipotle (NYSE:CM...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers. We analyze key trends and...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...
2024-07-09 10:30:11 ET Craig-Hallum analyst issues BUY recommendation for LGND on July 9, 2024 08:42AM ET. The previous analyst recommendation was Buy. LGND was trading at $86.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-07-09 10:00:05 ET Matt Hewitt from Craig-Hallum issued a price target of $140.00 for LGND on 2024-07-09 08:42:00. The adjusted price target was set to $140.00. At the time of the announcement, LGND was trading at $86.88. The overall price target consensus is at $117...